Non-invasive Determination of Myocardial Lipid Content in Fabry Disease by 1H-MR Spectroscopy

被引:12
作者
Petritsch, B. [1 ]
Koestler, H. [1 ]
Machann, W. [1 ]
Horn, M. [1 ]
Weng, A. M. [1 ]
Goltz, J. P. [1 ]
Hahn, D. [1 ]
Niemann, M. [2 ]
Weidemann, F. [2 ]
Wanner, C. [2 ]
Beer, M. [1 ]
机构
[1] Univ Klinikum Wurzburg, Inst Rontgendiagnost ZOM, D-97080 Wurzburg, Germany
[2] Univ Klinikum Wurzburg, Med Klin 1, D-97080 Wurzburg, Germany
来源
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN | 2012年 / 184卷 / 11期
关键词
cardiac; MR-imaging; MR-spectroscopy; genetic defects; molecular imaging; ENZYME REPLACEMENT THERAPY; CARDIOVASCULAR MAGNETIC-RESONANCE; TYPE-2; DIABETES-MELLITUS; IN-VIVO; MR SPECTROSCOPY; TESLA; TRIGLYCERIDE; HUMANS; REPRODUCIBILITY; QUANTIFICATION;
D O I
10.1055/s-0032-1313059
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: In Fabry disease (FD), a progressive deposition of sphingolipids is reported in different organs. The present study applied H-1 magnetic resonance spectroscopy (MRS) to investigate the myocardial lipid content in FD. Materials and Methods: In patients (PTS, n = 15) with genetically proven FD, H-1 MRS of the heart was acquired in the same examination as routine cardiac cine and late enhancement MR imaging. Healthy volunteers (n = 11) without history of cardiac disease served as control (CTL). Myocardial triglycerides in vivo were quantified in H-1 MRS. Left ventricular (LV) ejection fraction (EF) and late enhancement were assessed for the determination of LV systolic function, and onset or absence of myocardial fibrosis. Results: All H-1 MRS revealed resonances for intramyocardial triglycerides. Clinical parameters, e.g. EF (PTS 64 +/- 2 % vs. CTL 61 +/- 1 %) were similar in PTS and CTL or showed a non-significant trend (LV mass). Apart from a single patient with elevated myocardial triglycerides, no significant impact of Fabry disease on the triglyceride/water resonance ratio (PTS 0.47 +/- 0.11 vs. CTL 0.52 +/- 0.11 %) was observed in our patient cohort. Conclusion: A comprehensive cardiac evaluation of morphology, function as well as metabolism in Fabry PTS with suspected cardiac involvement is feasible in a single examination. No significant effect of myocardial triglyceride deposition could be observed in patients. The remarkably high myocardial triglyceride content in one patient with advanced FD warrants further studies in PTS with an extended history of the disease.
引用
收藏
页码:1020 / 1025
页数:6
相关论文
共 31 条
  • [1] Glycolipids from the red alga Chondria armata (Kutz.) Okamura
    Al-Fadhli, Ammar
    Wahidulla, Solimabi
    D'Souza, Lisette
    [J]. GLYCOBIOLOGY, 2006, 16 (10) : 902 - 915
  • [2] Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy
    Beer, Meinrad
    Weidemann, Frank
    Breunig, Frank
    Knoll, Anita
    Koeppe, Sabrina
    Machann, Wolfram
    Hahn, Dietbert
    Wanner, Christoph
    Strotmann, Jorg
    Sandstede, Jorn
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (10) : 1515 - 1518
  • [3] Fabry disease: Diagnosis and treatment
    Breunig, F
    Weidemann, F
    Beer, M
    Eggert, A
    Krane, V
    Spindler, M
    Sandstede, J
    Strotmann, J
    Wanner, C
    [J]. KIDNEY INTERNATIONAL, 2003, 63 : S181 - S185
  • [4] The role of echocardiographic deformation imaging in hypertrophic myopathies
    Cikes, Maja
    Sutherland, George R.
    Anderson, Lisa J.
    Bijnens, Bart H.
    [J]. NATURE REVIEWS CARDIOLOGY, 2010, 7 (07) : 384 - 396
  • [5] OBSERVATION OF CARDIAC LIPIDS IN HUMANS BY LOCALIZED H-1 MAGNETIC-RESONANCE SPECTROSCOPIC IMAGING
    DENHOLLANDER, JA
    EVANOCHKO, WT
    POHOST, GM
    [J]. MAGNETIC RESONANCE IN MEDICINE, 1994, 32 (02) : 175 - 180
  • [6] Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy
    Desnick, RJ
    Brady, R
    Barranger, J
    Collins, AJ
    Germain, DP
    Goldman, M
    Grabowski, G
    Packman, S
    Wilcox, WR
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (04) : 338 - 346
  • [7] Desnick Robert J, 2006, Nephrol Ther, V2 Suppl 2, pS172
  • [8] Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease
    Kalliokoski, RJ
    Kalliokoski, KK
    Sundell, J
    Engblom, E
    Penttinen, M
    Kantola, I
    Raitakari, OT
    Knuuti, J
    Nuutila, P
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (04) : 563 - 573
  • [9] Laser J A, 1985, Cardiovasc Clin, V15, P141
  • [10] Fabry disease:: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts
    Lücke, T
    Höppner, W
    Schmidt, E
    Illsinger, S
    Das, AM
    [J]. MOLECULAR GENETICS AND METABOLISM, 2004, 82 (01) : 93 - 97